ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial

SAN FRANCISCO & SYDNEY–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tools, today announced a strategic collaborative agreement with GenesisCare, an integrated cancer care provider. The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools guiding…
Click here to view original post

Advertisement — Advertise with Biotech Networks